Gilead Sciences (NASDAQ:GILD) Given New $190.00 Price Target at Wells Fargo & Company

Key Points

• Wells Fargo raised Gilead Sciences’ price target to $190 from $165 and maintained an “overweight” rating, implying approximately 10.4% upside from the stock’s current price.
• Gilead shares rose 3.9% to $172.11, near their 52-week high. The stock has a “Moderate Buy” consensus rating, with 23 analysts recommending Buy and six recommending Hold.
• Gilead’s latest quarterly results beat expectations, with revenue of $8.30 billion and EPS of $2.55; revenue increased 6.8% year over year. However, analysts and management continue to flag future pricing pressure on Biktarvy and related revenue headwinds.

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its price target hoisted by stock analysts at Wells Fargo & Company from $165.00 to $190.00 in a research report issued on Friday, Benzinga reports. The firm presently has an "overweight" rating on the biopharmaceutical company's stock. Wells Fargo & Company's target price suggests a potential upside of 10.40% from the company's current price.

A number of other equities research analysts have also recently weighed in on the company. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $160.00 to $170.00 and gave the company an "overweight" rating in a research note on Wednesday, October 7th. Cantor Fitzgerald increased their price objective on shares of Gilead Sciences from $155.00 to $175.00 and gave the company an "overweight" rating in a research report on Friday. Bank of America lifted their target price on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a "buy" rating in a report on Tuesday, October 20th. Leerink Partners cut shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Finally, UBS Group restated a "buy" rating on shares of Gilead Sciences in a research report on Friday. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $163.96.

Gilead Sciences Stock Up 3.9%

NASDAQ:GILD traded up $6.50 on Friday, hitting $172.11. 4,513,284 shares of the company's stock were exchanged, compared to its average volume of 6,782,397. The firm has a 50-day moving average price of $150.33 and a 200-day moving average price of $139.55. Gilead Sciences has a 52 week low of $114.02 and a 52 week high of $175.65. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The company has a market cap of $213.40 billion, a P/E ratio of -64.56 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company had revenue of $8.30 billion during the quarter, compared to analysts' expectations of $7.81 billion. During the same quarter last year, the company earned $2.47 EPS. Gilead Sciences's revenue for the quarter was up 6.8% compared to the same quarter last year. As a group, analysts expect that Gilead Sciences will post -0.48 EPS for the current fiscal year.

Insider Transactions at Gilead Sciences

In other news, Director Anthony Welters sold 18,000 shares of the company's stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the sale, the director directly owned 12,894 shares in the company, valued at approximately $1,916,306.28. This represents a 58.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O'Day sold 15,000 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total value of $2,229,600.00. Following the sale, the chief executive officer directly owned 577,133 shares in the company, valued at approximately $85,785,049.12. This trade represents a 2.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 111,000 shares of company stock worth $15,877,860. Corporate insiders own 0.30% of the company's stock.

Institutional Trading of Gilead Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Integrity Alliance LLC. grew its holdings in Gilead Sciences by 9.6% during the 3rd quarter. Integrity Alliance LLC. now owns 5,080 shares of the biopharmaceutical company's stock worth $757,000 after acquiring an additional 445 shares during the period. Integrity Advisory Solutions LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at about $207,000. First Nebraska Trust Co acquired a new stake in Gilead Sciences during the third quarter worth approximately $567,000. Aware Super Pty Ltd as trustee of Aware Super increased its holdings in Gilead Sciences by 15.1% in the third quarter. Aware Super Pty Ltd as trustee of Aware Super now owns 135,254 shares of the biopharmaceutical company's stock worth $20,160,000 after purchasing an additional 17,771 shares in the last quarter. Finally, Tucker Asset Management LLC lifted its stake in Gilead Sciences by 5.2% in the third quarter. Tucker Asset Management LLC now owns 4,175 shares of the biopharmaceutical company's stock valued at $622,000 after buying an additional 205 shares during the period. Institutional investors own 83.67% of the company's stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Quarterly results exceeded expectations: Gilead reported third-quarter revenue of $8.3 billion, up 6.8% year over year and approximately $500 million above consensus. Non-GAAP EPS of $2.55 also surpassed estimates of roughly $2.17–$2.19. Gilead Sciences Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: 2026 sales outlook was raised: Management now expects full-year product sales of approximately $31.0 billion to $31.3 billion, up from $30.1 billion to $30.4 billion, reflecting strong HIV demand and broader base-business growth. Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength
• Positive Sentiment: Growth beyond Biktarvy was encouraging: Trodelvy sales rose 41.7% year over year to $506 million, while management highlighted strong performance across its HIV portfolio. Gilead also agreed to acquire PepStar’s oral IL-23R inhibitor program for $1.275 billion upfront, supporting its future pipeline. Gilead Sciences Why I Remain Bullish After Q3
• Positive Sentiment: Analyst support improved: Needham raised its price target to $200 and maintained a Buy rating, while Cantor Fitzgerald increased its target to $175 and kept an Overweight rating after the earnings report. Analysts Increase Forecasts on Gilead Sciences
• Neutral Sentiment: Gilead secured a pan-Canadian reimbursement agreement for LYVDELZI, potentially expanding access to the primary biliary cholangitis treatment. The company also declared a quarterly dividend of $0.82 per share.
• Negative Sentiment: Longer-term pricing pressure remains: Management said Medicare pricing changes are expected to reduce Biktarvy’s price by about 38% beginning in 2028, creating an estimated $1.5 billion annual revenue headwind. The company also lowered or widened its 2026 EPS outlook, and some analysts cautioned that third-quarter HIV growth benefited from temporary inventory and channel effects. Gilead Hikes 2026 Sales Outlook
• Negative Sentiment: Gilead agreed to pay $45 million to settle Texas allegations involving unlawful incentives to healthcare providers, adding a legal and compliance expense.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.